Menarini Group and Radius Health, Inc. announce publication of...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
FLORENCE, Italy and BOSTON, May 20, 2022 /PRNewswire-AsiaNet/ -- -Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patients-PFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% vs. 8...
Authors: LATEST ASIANET NEWS RELEASES